Rohto Pharmaceutical Co.Ltd. (RPHCF) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rohto Pharmaceutical Co.L...

    PNK: RPHCF · Real-Time Price · USD
    20.09
    -6.54 (-24.56%)
    At close: Jan 24, 2025, 9:00 PM

    Rohto Pharmaceutical Income Statement

    Financials in JPY. Fiscal year is April - March.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
    Period Ending Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020
    Revenue
    		 71.07B 1.86B 1.84B 1.8B 1.76B 1.75B 1.7B 1.74B 1.74B 1.74B 47.9B 91.74B 130.14B 180.03B 181.05B 185.3B
    Cost of Revenue
    		 30.39B 779.77M 774.2M 757.31M 748.19M 738.94M 720.31M 729.93M 727.4M 730.98M 19.41B 36.86B 53.4B 72.17B 71.67B 73.3B
    Gross Profit
    		 40.68B 1.08B 1.07B 1.04B 1.01B 1.01B 982.84M 1.01B 1.01B 1.01B 28.49B 54.89B 76.73B 107.86B 109.38B 112B
    Operating Income
    		 5.03B 284.72M 277.39M 267.94M 249.09M 255.29M 245.36M 255.82M 248.88M 248.35M 6.45B 13.28B 16.81B 21.72B 23.17B 22.8B
    Interest Income
    		 435.57M 9.97M 8.58M 7.44M 7.11M 5.47M 4.76M 4.4M 3.21M 3.17M 78.27M 168.4M 260.73M 373M 430M 464M
    Pretax Income
    		 5.2B 289.01M 278.94M 266.32M 252.61M 252.94M 247.94M 258.35M 245.02M 262.97M 8.15B 14.14B 16.78B 19.49B 20B 21.24B
    Net Income
    		 4.96B 216.64M 213.26M 205.85M 194.38M 192.26M 181.53M 192.85M 183.97M 201.63M 5.05B 9.24B 10.94B 13.74B 14.09B 14.94B
    Selling & General & Admin
    		 506.96M 710.63M 709.14M 689.66M 679.45M 674.85M 661.46M 678.05M 683.47M 689.33M 517.76M 349.94M 204.92M n/a n/a n/a
    Research & Development
    		 58.03M 84.15M 81.91M 82.38M 81.58M 76.48M 76.02M 75.9M 76.39M 75.52M 58.68M 37.22M 20.15M n/a n/a n/a
    Other Expenses
    		 35.77B 340M -433M -397M -63M 240M 894M 642M 246M 298M 190M 96M 112M -212M -183M 10M
    Operating Expenses
    		 35.64B 794.77M 791.04M 772.04M 761.03M 751.33M 737.49M 753.95M 759.87M 764.86M 22.05B 41.6B 59.93B 86.66B 86.74B 89.73B
    Interest Expense
    		 17.24M 1.64M 1.68M 1.71M 1.82M 2.48M 2.33M 2.25M 2.12M 1.48M 33.09M 65.72M 97.43M 127M 126M 124M
    Selling & Marketing Expenses
    		 n/a 46.47B 46.47B 46.47B 46.47B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Cost & Expenses
    		 66.04B 1.57B 1.57B 1.53B 1.51B 1.49B 1.46B 1.48B 1.49B 1.5B 41.45B 78.46B 113.33B 158.83B 158.41B 163.02B
    Income Tax Expense
    		 153.59M 70.86M 64.38M 59.5M 57.85M 59.47M 64.96M 63.97M 59.87M 59.78M 3.09B 4.9B 5.82B 5.91B 6.05B 6.42B
    Shares Outstanding (Basic)
    		 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M 228.14M n/a n/a 228.14M
    Shares Outstanding (Diluted)
    		 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M 228.8M n/a n/a 228.81M
    EPS (Basic)
    		 21.75 0.96 0.94 0.91 0.86 0.85 0.81 0.86 0.82 0.89 0.65 0.41 7.88 7.66 7.66 7.66
    EPS (Diluted)
    		 21.69 0.96 0.94 0.91 0.86 0.85 0.80 0.85 0.81 0.88 0.65 0.41 7.86 7.64 7.64 7.64
    EBITDA
    		 41.71B 41.57B 39.26B 37.11B 34.53B 34.25B 32.22B 31.46B 28.22B 29.71B 26.39B 26.06B 23.57B 21.7B 22.49B 22.33B
    EBIT
    		 41.71B 41.57B 39.26B 37.11B 34.53B 34.25B 32.22B 31.46B 28.22B 29.71B 27.97B 26.59B 22.85B 19.62B 20.13B 21.36B
    Depreciation & Amortization
    		 371.64M 29.68M 14.17M 169.59K 167.9K 178.96K 245.63K 209.61K 228.49K 245K 271.92K 241.66K 236.41K 220.15K 218.9K 214.21K

    Add to Watchlist